- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00589888
FFA-Induced Hypertension and Endothelial Dysfunction
Free Fatty Acids-Induced Hypertension and Endothelial Dysfunction in Obese Subjects
Study Overview
Status
Conditions
Detailed Description
Insulin resistance has been implicated as the central mechanism in the development of several cardiovascular risk factors including hypertension, diabetes, lipid disorders, and coagulation disorders. Recent evidence suggests that increased levels of a circulation fat (free fatty acids or FFAs) are a leading candidate causing insulin resistance. Our preliminary studies in indicate that, in addition to insulin resistance, the infusion of Intralipid and heparin to increase FFAs resulted in a significant rise in systolic and diastolic blood pressure, impaired endothelial (vascular) function, and increased inflammatory markers in obese African Americans with and without diabetes. The effects of FFA on insulin action are well established; however, the blood pressure and vascular effects of FFAs infusion in obese subjects have not been fully investigated. We hypothesize that observed changes in blood pressure are the result of acute endothelial dysfunction, and/or increased activation of the autonomic nervous system. No previous studies have attempted to determine a dose response effect of increasing FFA on blood pressure. In addition, it is not know if increased FFAs by repeated oral fat load results in similar blood pressure than intravenous lipid infusion. Accordingly, we propose: 1) a systematic evaluation of the effects of increasing FFA levels on blood pressure and endothelial (vascular) function, and 2) determine the effects of comparable increases in FFA concentration via intravenous infusion of Intralipid or by repeated oral fat load on blood pressure, insulin resistance and endothelial dysfunction in obese subjects.
A group of obese normotensive subjects will be admitted to the Grady Clinical Research Center or to the Outpatient Research Unit in the Grady Diabetes Clinic on five occasions. In four of these admissions, research subjects will receive an 8-hour intravenous infusion, in random order, of increasing Intralipid concentration (10 ml, 20 ml, 40 ml per hour) or normal saline (40 ml per hour). During the final admission, research subjects will receive an oral liquid fat diet every 2 hours for 8-hours. The effect of increased FFAs on blood pressure and endothelial (vascular) function via intravenous infusion and via oral fat load therapy will be assessed.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30303
- Grady Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females between the ages of 18 and 65 years.
- Definition: obese = BMI ≥ 30 kg/m2
- Blood pressure < 140/80 mm Hg and no prior history of hypertension
Exclusion Criteria:
- History of hypertension or previous history of antihypertensive drug therapy.
- Current tobacco use
- Fasting triglyceride levels > 250 mg/dL during the stabilization period.
- Liver disease (ALT 2.5x > upper limit of normal), or other significant medical or surgical illness, including myocardial ischemia, congestive heart failure, liver failure, and infectious processes.
- Serum creatinine ≥1.5 mg/dL for males, or ≥ 1.4 mg/dL for females.
- History of drug or alcohol abuse within the last 5 years.
- Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
- Female subjects are pregnant or breast feeding at time of enrollment into the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Intralipid 20%@ 20cc/hour
Intralipid 20% IV infusion at 20cc/hour
|
In this arm subjects received Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours.
The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids.
During the intralipid infusion studies, subjects remained fasting
Other Names:
|
Active Comparator: Intralipid 20% @ 40cc/hour
Intralipid 20% IV infusion at 40cc/hour
|
In this arm subjects received Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours.
In this arm subjects will receive Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours.
The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids.
During the intralipid infusion studies, subjects remained fasting.
Other Names:
|
Placebo Comparator: Normal Saline infusion @ 40cc/hour
Normal Saline continuous IV infusion at 40cc/hour for 8 hours
|
In this arm subjects received 0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours.
Other Names:
|
Active Comparator: 32-gram oral fat load
32-gram oral fat load once
|
In this arm subjects received oral liquid fat load prepared by the General Clinical Research Center (GCRC) at baseline and every 2 hours for 6 hours.
Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids.
The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
|
Active Comparator: 64-gram oral fat load
64-gram oral fat load once
|
In this arm subjects received 60-gram oral fat load intake at baseline and every 2 hours for 6 hours prepared by the General Clinical Research Center (GCRC).
Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids.
The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Systolic Blood Pressure to After Completing an 8-hour Normal Saline Infusion in Obese Normotensive Subjects.
Time Frame: Baseline and at the end of the 8-hours
|
To study the effects of high dose oral fat load on systolic blood pressure (SBP) in healthy obese subjects, subject's baseline SBP is compared to SBP after the infusion.
Blood Pressure (BP) was measured with a manual cuff in triplicate on admission when patient was in Supine position.
The Blood pressure was measured at admission and at end of the fat load.
The BP from the admission are compared to BP after the fat load.
A normal systolic blood pressure is lower than 120 mmHg; elevated blood pressure if the systolic reading is 120-129 mmHg.
A level above 140 mmHg is considered hypertension.
|
Baseline and at the end of the 8-hours
|
Change in Systolic Blood Pressure From Baseline to After Completing an 8-hour 20% Intralipid @ 20cc/hr Infusion in Obese Normotensive Subjects.
Time Frame: Baseline and at the end of the 8-hours
|
To study the effects of low dose intravenous (IV) fat infusion on systolic blood pressure (SBP) in healthy obese subjects, subject's baseline SBP is compared to SBP after the infusion.
Blood Pressure (BP) was measured with a manual cuff in triplicate on admission when patient was in Supine position.
The Blood pressure was measured at admission and at every 2 hours till the end of infusion.
The BP from the admission are compared to BP after the infusion.A normal systolic blood pressure is lower than 120 mmHg; elevated blood pressure if the systolic reading is 120-129 mmHg.
A level above 140 mmHg is considered hypertension.
|
Baseline and at the end of the 8-hours
|
Changes in Systolic Blood Pressure From Baseline to After Completing an 8-hour 20% Intralipid @ 40cc/hr Infusion in Obese Normotensive Subjects
Time Frame: Baseline and at the end of the 8-hours
|
To study the effects of high dose intravenous (IV) fat infusion on systolic blood pressure (SBP) in healthy obese subjects, subject's baseline SBP is compared to SBP after the infusion.
Blood Pressure (BP) was measured with a manual cuff in triplicate on admission when patient was in Supine position.
The Blood pressure was measured at admission and at every 2 hours till the end of infusion.
The BP from the admission are compared to BP after the infusion.
A normal systolic blood pressure is lower than 120 mmHg; elevated blood pressure if the systolic reading is 120-129 mmHg.
A level above 140 mmHg is considered hypertension.
|
Baseline and at the end of the 8-hours
|
Change in Systolic Blood Pressure From Baseline to After Completing an Oral 32-gram Fat Load in Obese Normotensive Subjects.
Time Frame: Baseline and at the end of the 8-hours
|
To study the effects of oral low dose fat load on systolic blood pressure (SBP) in healthy obese subjects, subject's baseline SBP is compared to SBP after the infusion.
Blood Pressure (BP) was measured with a manual cuff in triplicate on admission when patient was in Supine position.The Blood pressure was measured at admission and at end of the fat load.
The BP from the admission are compared to BP after the fat load.
A normal systolic blood pressure is lower than 120 mmHg; elevated blood pressure if the systolic reading is 120-129 mmHg.
A level above 140 mmHg is considered hypertension.
|
Baseline and at the end of the 8-hours
|
Changes in Systolic Blood Pressure From Baseline to After Completing an Oral 64-gram Fat Load in Obese Normotensive Subjects
Time Frame: at the end of the 8 hours
|
To study the effects of high dose oral fat load on systolic blood pressure (SBP) in healthy obese subjects, subject's baseline SBP is compared to SBP after the infusion.
Blood Pressure (BP) was measured with a manual cuff in triplicate on admission when patient was in Supine position.
The Blood pressure was measured at admission and at end of the fat load.
The BP from the admission are compared to BP after the fat load.
A normal systolic blood pressure is lower than 120 mmHg; elevated blood pressure if the systolic reading is 120-129 mmHg.
A level above 140 mmHg is considered hypertension.
|
at the end of the 8 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Flow-mediated Dilation (FMD) of Endothelium-dependent Brachial Artery From Baseline to After Completing a Specific Intervention in Obese Normotensive Subjects.
Time Frame: Baseline and at the end of the 8-hours
|
Endothelium-dependent brachial artery dilatation was assessed as a measurement of endothelial function using established methodology.
Briefly, ultrasound images of the brachial artery were obtained at baseline under standardized conditions and 60 s after induction of reactive hyperemia by 5-min cuff occlusion of the forearm.
Image landmarks as well as surface markers were utilized to ensure anatomic consistency between serial imaging studies.
All images were digitized online, and arterial diameters were measured with customized software by individuals blinded to the clinical and laboratory status of the subjects.
Flow-mediated dilatation (FMD) was expressed as the percentage increase in diameter from baseline.
It is measured in percentage.
|
Baseline and at the end of the 8-hours
|
Change in Blood Glucose Levels From Baseline to 6-8 Hours After Intervention Among Obese Healthy Subjects
Time Frame: Baseline and at the end of the 8-hours
|
The blood glucose level is the amount of glucose present in the blood of humans.
Many factors affect a person's blood sugar level.
The body's homeostatic mechanism of blood sugar regulation (known as glucose homeostasis), when operating normally, restores the blood sugar level to a narrow range of about 4.4 to 6.1 mmol/L (79 to 110 mg/dL) (as measured by a fasting blood glucose test).
The study aims to study the effects of these interventions on blood glucose levels among obese healthy subjects.
|
Baseline and at the end of the 8-hours
|
Change in C-peptide Concentration Levels From Baseline to After Specific Intervention Among the Healthy Obese Subjects
Time Frame: baseline and after 8 hours after admission
|
C-peptide is a peptide composed of 31 amino acids.
It is released from the pancreatic beta-cells during cleavage of insulin from proinsulin.
It is mainly excreted by the kidney, and its half-life is 3-4 times longer than that of insulin.
The reference range of C-peptide is 0. 8-3 ng/ml.
The C-peptide test is a tool to monitor and treat diabetes.
It shows how well your body makes insulin, which moves sugar (or "glucose") from your blood into your cells.
|
baseline and after 8 hours after admission
|
Change in Blood Insulin Levels From Baseline to After Intervention Among the Normal Obese Subjects
Time Frame: Baseline and at the end of the 8-hours
|
Insulin is an anabolic hormone that promotes glucose uptake, glycogenesis, lipogenesis, and protein synthesis of skeletal muscle and fat tissue through the tyrosine kinase receptor pathway.
In addition, insulin is the most important factor in the regulation of plasma glucose homeostasis, as it counteracts glucagon and other catabolic hormones like epinephrine, glucocorticoid, and growth hormone.
Normal fasting insulin levels is < 25 milli-International unit/litre
|
Baseline and at the end of the 8-hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Guillermo Umpierrez, MD, Emory University SOM/GCRC
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00041116
- IRB 668-2006 (Other Identifier: Other)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on Intralipid 20% @ 20cc/hour
-
Indiana UniversityActive, not recruitingComparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical NeonatesCholestasis of Parenteral NutritionUnited States
-
Fresenius KabiTerminatedHospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 DaysUnited States
-
Fresenius KabiTerminatedMalnutrition, ChildUnited States
-
Ain Shams UniversityRecruiting
-
Woman's Health University Hospital, EgyptCompleted
-
Cairo UniversityCompleted
-
Ain Shams UniversityUnknown
-
Nkanyiso HadebeUnknown
-
Methodist Research Institute, IndianapolisTerminatedAcute Respiratory Distress SyndromeUnited States